Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Chemopreventive Agent Development
Sponsor
National Cancer Institute (NCI)
Status
Completed
NCT ID
NCT00489372
This randomized phase I trial is studying the side effects and best dose of Se-methyl-seleno-L-cysteine in healthy adult men. Studying samples of blood, urine, and toenail clippings in the laboratory from healthy men receiving Se-methyl-seleno-L-cysteine may help doctors learn more about how Se-methyl-seleno-L-cysteine works in the body.
Intervention
Se-methyl-seleno-L-cysteine, laboratory biomarker analysis, pharmacological study, placebo
Condition
Healthy, no Evidence of Disease
Investigators
Raymond Bergan